Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, mono-centric, phase I-Ib trial of Tivantinib in
combination with Pemetrexed and Carboplatin as first-line therapy in patients with advanced
or metastatic cancer suitable for a Carboplatin and Pemetrexed regimen as part of their
specific therapy.